22:44 , Apr 25, 2019 |  BC Extra  |  Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
19:21 , Apr 11, 2019 |  BC Extra  |  Clinical News

Gilead’s NASH combo data suggest benefit, safety

Phase II combination data presented by Gilead at EASL could begin to lay the groundwork for what MOAs will be essential parts of combinations in non-alcoholic steatohepatitis. In a Phase II proof-of-concept trial in 20...
01:40 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor. The...
00:01 , Feb 12, 2019 |  BC Extra  |  Clinical News

Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis

Gilead Sciences Inc. (NASDAQ:GILD) said selonsertib (GS-4997) missed the primary endpoint in the Phase III STELLAR-4 trial to treat compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Selonsertib is an oral small molecule ASK1 inhibitor. The...
17:54 , Jan 11, 2019 |  BC Week In Review  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
03:04 , Jan 7, 2019 |  BC Extra  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
19:24 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead grows fibrosis pipeline with Scholar Rock deal

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to expand its fibrotic pipeline. Gilead received options to two...
23:42 , Dec 19, 2018 |  BC Extra  |  Company News

Gilead grows fibrosis pipeline with Scholar Rock deal

Gilead Sciences Inc. (NASDAQ:GILD) acquired options to license transforming growth factor β 1 (TGFβ1) programs from Scholar Rock Holding Corp. (NASDAQ:SRRK) as the bellwether looks to expand its fibrotic pipeline. Gilead received options to two...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...